BACKGROUND AND OBJECTIVES: P120-catenin (p120ctn) is a member of the E-cadherin-catenin cell-cell adhesion complex. Impairment of one or more of the components of this complex is associated with tumorigenesis. The role of p120ctn in malignancy is not clear yet. We studied the in vivo expression and cellular localization of p120ctn in adenocarcinomas of the gastroesophageal junction. METHODS: Immunohistochemical staining for p120ctn was performed on 96 tumor samples, 20 cases of Barretts metaplasia and 13 lymph node metastases. The relationship with pathological characteristics and patient survival was also assessed. RESULTS: Loss of normal surface p120ctn expression was found in 4/20 (20%) Barretts metaplasia, in 65/96 (68%) tumors, and 11/13 (85%) lymph node metastases. Nuclear immunoreactivity for p120ctn was seen in five tumors. Loss of normal expression of p120ctn was associated with a higher tumor grade (P < 0.0001) but not with pTNM-stage. Reduced expression of p120ctn was correlated with poor survival (P = 0.0002). Cox regression analysis showed that p120ctn is an independent prognostic marker. CONCLUSIONS: Abnormal p120ctn expression is frequently seen in adenocarcinomas of the gastroesophageal junction, and may be a useful as a prognostic marker in these tumors. (c) 2005 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES:P120-catenin (p120ctn) is a member of the E-cadherin-catenin cell-cell adhesion complex. Impairment of one or more of the components of this complex is associated with tumorigenesis. The role of p120ctn in malignancy is not clear yet. We studied the in vivo expression and cellular localization of p120ctn in adenocarcinomas of the gastroesophageal junction. METHODS: Immunohistochemical staining for p120ctn was performed on 96 tumor samples, 20 cases of Barretts metaplasia and 13 lymph node metastases. The relationship with pathological characteristics and patient survival was also assessed. RESULTS: Loss of normal surface p120ctn expression was found in 4/20 (20%) Barretts metaplasia, in 65/96 (68%) tumors, and 11/13 (85%) lymph node metastases. Nuclear immunoreactivity for p120ctn was seen in five tumors. Loss of normal expression of p120ctn was associated with a higher tumor grade (P < 0.0001) but not with pTNM-stage. Reduced expression of p120ctn was correlated with poor survival (P = 0.0002). Cox regression analysis showed that p120ctn is an independent prognostic marker. CONCLUSIONS: Abnormal p120ctn expression is frequently seen in adenocarcinomas of the gastroesophageal junction, and may be a useful as a prognostic marker in these tumors. (c) 2005 Wiley-Liss, Inc.
Authors: Emhonta Johnson; Darcie D Seachrist; Carlos M DeLeon-Rodriguez; Kristen L Lozada; John Miedler; Fadi W Abdul-Karim; Ruth A Keri Journal: J Biol Chem Date: 2010-07-01 Impact factor: 5.157
Authors: K Talvinen; J Tuikkala; M Nykänen; A Nieminen; J Anttinen; O S Nevalainen; S Hurme; T Kuopio; P Kronqvist Journal: J Cancer Res Clin Oncol Date: 2010-02-12 Impact factor: 4.553
Authors: Seth R Ogden; Lydia E Wroblewski; Christiane Weydig; Judith Romero-Gallo; Daniel P O'Brien; Dawn A Israel; Uma S Krishna; Barbara Fingleton; Albert B Reynolds; Silja Wessler; Richard M Peek Journal: Mol Biol Cell Date: 2008-07-23 Impact factor: 4.138